DK148889A - Fremgangsmaade til foroegelse af extracellulaert adenosin og til stabilisering af mastceller - Google Patents

Fremgangsmaade til foroegelse af extracellulaert adenosin og til stabilisering af mastceller

Info

Publication number
DK148889A
DK148889A DK148889A DK148889A DK148889A DK 148889 A DK148889 A DK 148889A DK 148889 A DK148889 A DK 148889A DK 148889 A DK148889 A DK 148889A DK 148889 A DK148889 A DK 148889A
Authority
DK
Denmark
Prior art keywords
district heating
checking apparatus
detecting leaks
heating facilities
adenosine
Prior art date
Application number
DK148889A
Other languages
English (en)
Other versions
DK175978B1 (da
DK148889D0 (da
Inventor
Harry Edward Gruber
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of DK148889D0 publication Critical patent/DK148889D0/da
Publication of DK148889A publication Critical patent/DK148889A/da
Application granted granted Critical
Publication of DK175978B1 publication Critical patent/DK175978B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
  • Discharge Heating (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Examining Or Testing Airtightness (AREA)
DK198901488A 1987-07-29 1989-03-28 Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose DK175978B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7965787 1987-07-29
US07/079,657 US4912092A (en) 1986-03-27 1987-07-29 Methods for increasing extracellular adenosine and for stabilizing mast cells
US8802527 1988-07-29
PCT/US1988/002527 WO1989000854A1 (en) 1987-07-29 1988-07-29 Methods for increasing extracellular adenosine and for stabilizing mast cells

Publications (3)

Publication Number Publication Date
DK148889D0 DK148889D0 (da) 1989-03-28
DK148889A true DK148889A (da) 1989-05-29
DK175978B1 DK175978B1 (da) 2005-10-17

Family

ID=22151963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198901488A DK175978B1 (da) 1987-07-29 1989-03-28 Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose

Country Status (13)

Country Link
US (1) US4912092A (da)
EP (2) EP0672418A3 (da)
JP (1) JPH02500916A (da)
AT (1) ATE135580T1 (da)
AU (3) AU2315088A (da)
BR (1) BR8807151A (da)
CA (1) CA1335716C (da)
DE (1) DE3855120T2 (da)
DK (1) DK175978B1 (da)
ES (1) ES2087061T3 (da)
FI (1) FI891463A0 (da)
GR (1) GR3019389T3 (da)
WO (1) WO1989000854A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597683B1 (fr) * 1986-04-22 1992-07-31 Battarel Claude Clavier a interrruption de rayonnement.
EP0427799B1 (en) * 1989-01-24 1994-11-30 Gensia, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
AU643235B2 (en) * 1989-09-15 1993-11-11 Gensia Pharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US5366440A (en) * 1989-10-06 1994-11-22 The Beth Israel Hospital Association Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US6180616B1 (en) 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
US5777100A (en) * 1990-08-10 1998-07-07 Gensia Inc. AICA riboside analogs
IL99124A (en) * 1990-08-10 1998-02-22 Gensia Pharma Substituted imidazole analogs of aica riboside
IL99125A0 (en) * 1990-08-10 1992-07-15 Gensia Pharma Derivatives of imidazole analog of aica riboside and their use
US5308837A (en) * 1990-08-22 1994-05-03 Merrell Dow Pharmaceuticals Inc. 5'-amine substituted adenosine analogs as immunosuppressants
AU665184B2 (en) * 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
US5236908A (en) * 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
WO1993003734A1 (en) * 1991-08-23 1993-03-04 Gensia, Inc. Method for lowering blood lipid levels
IL103294A0 (en) * 1991-09-30 1993-05-13 Gensia Pharma Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
WO1994017809A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine deaminase inhibitor therapies
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
WO1995001097A1 (en) * 1993-06-30 1995-01-12 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing
US6342484B1 (en) 1993-06-30 2002-01-29 Board Of Regents, The University Of Texas Systems Method and compositions for promotion of wound treatment
US5366960A (en) * 1993-08-26 1994-11-22 Warner-Lambert Company Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol
US5859017A (en) * 1994-04-01 1999-01-12 Cell Therapeutics, Inc. Method for inhibiting mast cell and basophil activation
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
EP1174141A3 (en) * 1996-01-23 2003-04-23 ICN Pharmaceuticals, Inc. Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
CA2267138A1 (en) * 1996-10-03 1998-04-09 The Trustees Of The University Of Pennsylvania Compositions and methods for the identification and treatment of patients at risk for heart failure
WO1999024038A1 (en) 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
US6800616B2 (en) 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
US6680292B1 (en) 1998-11-20 2004-01-20 The Salk Institute For Biological Studies Pharmaceutical composition comprising ribavirin and growth factors and methods of use
WO2000030656A1 (en) * 1998-11-20 2000-06-02 The Salk Institute For Biological Studies Neuron stimulation by ribavirin, and analogs thereof
US6579857B1 (en) 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
AU7629200A (en) * 1999-08-09 2001-03-05 Trustees Of Boston University Method of maintaining vascular integrity using aicar (5-amino-4-imidazole riboside) and related compounds
WO2001043731A2 (en) * 1999-12-16 2001-06-21 Alcon, Inc. Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
WO2001071342A2 (en) * 2000-03-23 2001-09-27 Novartis Ag Identification of mast cell/basophil activation inhibitors
US20020086835A1 (en) * 2000-05-22 2002-07-04 Law William R. Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome
AU2001268236A1 (en) * 2000-06-06 2001-12-17 Trustees Of Boston University Use of aicar and related compounds
AU2001268474A1 (en) * 2000-06-16 2002-01-02 Brigham Young University Use of amp kinase activators for treatment of type 2 diabetes and insulin resistance
US20030212034A1 (en) * 2001-06-11 2003-11-13 Winder William W Method of treatment of obesity and paralyzed muscle and ergogenic aids
US20030212013A1 (en) * 2001-06-14 2003-11-13 Winder William W Use of amp kinase activators for treatment type 2 diabetes and insulin resistance
ES2192495B1 (es) * 2002-03-21 2005-02-16 Universidad De Barcelona Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
US20060079479A1 (en) * 2004-10-13 2006-04-13 Italo Biaggioni Methods of inducing vasodilation
US7687473B2 (en) * 2005-01-07 2010-03-30 Health Research, Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
JP2008534601A (ja) 2005-03-28 2008-08-28 ペリコー セラピューティクス， インコーポレイテッド 患者における副作用を予防または減少するための方法、組成物および処方物
WO2007017512A1 (en) * 2005-08-09 2007-02-15 Cellzome Ag Treatment of inflammatory diseases
WO2007017505A2 (en) * 2005-08-09 2007-02-15 Cellzome Ag Treatment of metabolic diseases
US20070082859A1 (en) * 2005-10-07 2007-04-12 Stover Richard R Formulations of AICA riboside
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
US20090185973A1 (en) * 2008-01-22 2009-07-23 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
WO2010040110A1 (en) * 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US20100261666A1 (en) * 2009-04-14 2010-10-14 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of myocardial dysfunction associated with sirs or sepsis
BR112012012476A2 (pt) * 2009-11-25 2015-09-15 Nestec Sa "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
US8895520B2 (en) 2011-10-26 2014-11-25 Universite Nice Sophia Antipolis Method for treating a human patent suffering from Myeloid Neoplasias using 5-aminoimidazole-4-carboxamide
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
WO2017017540A1 (en) 2015-06-08 2017-02-02 Remedeye Inc Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions, and methods for producing same
CN112739352B (zh) * 2018-08-06 2024-01-23 斯凯拉克生物科技有限责任公司 活化amp-活化的蛋白激酶的化合物及其用途
US11779590B2 (en) 2020-10-30 2023-10-10 Skylark Bioscience Llc AMP-activated protein kinase activating compounds and uses thereof
WO2024216536A1 (zh) * 2023-04-19 2024-10-24 百瑞全球有限公司 制备核糖核苷或其衍生物的方法、生物酶制剂及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AU529532B2 (en) * 1978-09-18 1983-06-09 Commonwealth Scientific And Industrial Research Organisation Frequency response analyser
EP0066909A3 (en) * 1981-05-15 1984-03-07 FISONS plc Imidazole derivatives, pharmaceutical compositions containing them and processes for their production
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
ATE135914T1 (de) * 1986-03-27 1996-04-15 Gensia Inc Aica riboside zur prophylaktischen behandlung von krankheiten mit einer verminderten durchblutung.

Also Published As

Publication number Publication date
ATE135580T1 (de) 1996-04-15
CA1335716C (en) 1995-05-30
EP0672418A2 (en) 1995-09-20
ES2087061T3 (es) 1996-07-16
AU2315088A (en) 1989-03-01
DE3855120D1 (de) 1996-04-25
DE3855120T2 (de) 1996-09-19
BR8807151A (pt) 1989-10-17
FI891463A7 (fi) 1989-03-28
AU687112B2 (en) 1998-02-19
FI891463L (fi) 1989-03-28
FI891463A0 (fi) 1989-03-28
GR3019389T3 (en) 1996-06-30
EP0301900B1 (en) 1996-03-20
EP0301900A3 (en) 1989-09-20
EP0672418A3 (en) 1996-05-29
US4912092A (en) 1990-03-27
AU1285592A (en) 1992-06-04
DK175978B1 (da) 2005-10-17
JPH02500916A (ja) 1990-03-29
AU8039394A (en) 1995-03-09
DK148889D0 (da) 1989-03-28
EP0301900A2 (en) 1989-02-01
WO1989000854A1 (en) 1989-02-09

Similar Documents

Publication Publication Date Title
FI891463A0 (fi) Foerfarande foer att oeka extracellulaer adenosin och att stabilisera mastceller.
JPS57501662A (da)
DE3674986D1 (de) Dopplerkatheter.
IT1151774B (it) Procedimento e dispositivo per misurare il tempo di coagulazione del sangue
JPS5356892A (en) Disposable piping unit for use in apparatus for lavage of blood
GB2163555B (en) Apparatus and process for determining the deformability of the red corpuscles in the blood
FI890215A0 (fi) Menetelmä ja laite verenpaineen mittaamiseksi
EP0259857A3 (en) Method of assaying physiologically active substances
IT1152415B (it) Procedimento ed apparecchiatura per determinare e controllare il contenuto di gas nel sangue di un paziente
NO143691C (no) Fremgangsmaate og apparat for paavisning av en blodlekkasje i en hemodialyse-enhet
SE8400587D0 (sv) Sett att bestemma isotransferriner
IT1116032B (it) Composizione e procedimento per la determinazione della concentrazione del glucosio in fluidi corporei
DE2961554D1 (en) Device for the transcutaneous determination of the partial pressure of gas in blood
JPS56152639A (en) Sensor for measuring carbon dioxide gas in blood through skin
JPS53139785A (en) Detecting of bacteria in blood
JPS55113437A (en) Cuff device in blood pressure measuring system
EP0292019A3 (en) Process for measuring the content of component in vital fluid such as urine and blood
JPS57196965A (en) Measuring of gas partial pressure in blood
SE7903631L (sv) Forfarande for bestemning av kalciumnivan i blod
PT77941A (en) Ophthalmoscopic instrument for testing in a quick and recordable way the main clinical parameters of sight
UA7064A1 (uk) Спосіб визначення функціонального стану організму
DE3572033D1 (en) Method for diagnosis of a.i.d.s.
JPS5789853A (en) Measuring of gas concentration blood from skin
JPS56100046A (en) Sensor for measuring blood gas through skin
JPS56152631A (en) Sensor for measuring carbon dioxide gas in blood through skin

Legal Events

Date Code Title Description
PUP Patent expired